PAR4 Antibody (YA5006)
(Synonyms: PAWR; PAR4; PRKC apoptosis WT1 regulator protein; Prostate apoptosis response 4 protein; Par-4)PAR4 Antibody (YA5006) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PAR4.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, IHC-P, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in Ascitic fluid containing 0.03% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:1000 | 1:10000 |
Product Details
PAR4 Antibody (YA5006) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PAR4.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 37 kDa;
Purified recombinant fragment of PAR4(aa1-330) expressed in E. Coli. The exact sequence is proprietary to MCE.
Endogenous
affinity purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in Ascitic fluid containing 0.03% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Protease-activated receptor 4 (PAR4/F2RL3) functions as a thrombin-responsive platelet receptor that supports hemostasis and thrombosis through platelet activation[1]. Mechanistically, PAR4 signaling contributes to calcium mobilization, dense granule secretion, P-selectin expression, platelet aggregation, and platelet-leukocyte interactions[2][3]. In thrombosis models, PAR4 is required for platelet thrombus propagation but not for the initial platelet deposition after vascular injury[2]. Compared with PAR1, PAR4 requires higher thrombin concentrations for proteolysis and produces more sustained platelet activation, making PAR4 a distinct late-phase thrombin receptor[4]. This isoform distinction supports research designs that separate early PAR1-driven platelet responses from later PAR4-dependent thrombus growth[2][4]. For experimental applications, PAR4 agonist peptides and selective antagonists such as BMS-986120 enable targeted analysis of PAR4-dependent platelet activation, high-shear thrombus formation, and antithrombotic efficacy with limited bleeding signals in reported models[5][6].
-
Subcellular Localization
Cytoplasm; Nucleus
-
Expression
Tissue_specificity:Widely expressed. Elevated expression is found in a variety of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) , Alzheimer's disease, Parkinson's disease, Huntington's disease, and stroke. Downregulated expression is found in a variety of cancers.
Induction:By apoptosis -
Subunit
Homooligomer. Interacts (via the C-terminal region) with WT1 (PubMed:8943350). Interacts with THAP1 (PubMed:12717420). Interacts with AATF (PubMed:14627703). Interacts with BACE1 (PubMed:15671026).
-
SwissProt ID
-
Synonyms
PAWR; PAR4; PRKC apoptosis WT1 regulator protein; Prostate apoptosis response 4 protein; Par-4
Documentation
[1]. Sambrano GR, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001 Sep 6;413(6851):74-8. [Content Brief]
[2]. Vandendries ER, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):288-92. [Content Brief]
[3]. Rigg RA, et al. Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets. 2019;30(1):126-135. [Content Brief]
[4]. Han X, et al. PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. [Content Brief]
[5]. Wilson SJ, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. [Content Brief]
[6]. Wilson SJ, et al. PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol. 2017;37(3):448-56. [Content Brief]
Powered by Bioz
